Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CD79B | P40259 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | CD99 | P14209 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20347279 | 0.93 | NT5E (0.48) | NT5EHTR2CHTR2BCD79BALDH1A1 | |
| SCHEMBL20347283 | 0.86 | NT5E (0.44) | NT5EHTR2CHTR2BALDH1A1LMNA | |
| SCHEMBL20334139 | 0.84 | NT5E (0.43) | NT5EHTR2CHTR2BALDH1A1LMNA | |
| SCHEMBL20333401 | 0.83 | NT5E (0.41) | NT5ECD79BADORA3CD99 | |
| SCHEMBL19961888 | 0.83 | NT5E (0.46) | NT5ECD79BALDH1A1LMNATP53 | |
| SCHEMBL20347277 | 0.82 | NT5E (0.61) | NT5E | |
| SCHEMBL20347249 | 0.82 | NT5E (0.36) | NT5EHTR2CHTR2BCD79BALDH1A1 | |
| SCHEMBL19961905 | 0.81 | LMNA (0.43) | NT5EHTR2CHTR2BCD79BALDH1A1 | |
| SCHEMBL20305373 | 0.81 | NT5E (0.45) | NT5EHTR2CHTR2BCD99 | |
| SCHEMBL19961874 | 0.79 | PDE2A (0.49) | NT5EALDH1A1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | NT5E 1/4885HTR2C 448/4885HTR2B 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.